463 related articles for article (PubMed ID: 30471652)
21. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Dimopoulos MA; Špička I; Quach H; Oriol A; Hájek R; Garg M; Beksac M; Bringhen S; Katodritou E; Chng WJ; Leleu X; Iida S; Mateos MV; Morgan G; Vorog A; Labotka R; Wang B; Palumbo A; Lonial S;
J Clin Oncol; 2020 Dec; 38(34):4030-4041. PubMed ID: 33021870
[TBL] [Abstract][Full Text] [Related]
22. Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma.
Li S; Zhang D; Yang L; Huang C; Niu T; Gong Y
Cancer Med; 2023 Mar; 12(6):6523-6535. PubMed ID: 36377601
[TBL] [Abstract][Full Text] [Related]
23. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
24. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
Tanaka K; Toyota S; Akiyama M; Wakimoto N; Nakamura Y; Najima Y; Doki N; Kakihana K; Igarashi A; Kobayashi T; Ohashi K; Kudo D; Shinagawa A; Takano H; Fujio T; Okoshi Y; Hori M; Kumagai T; Saito T; Mukae J; Yamamoto K; Tsutsumi I; Komeno T; Yoshida C; Yamamoto M; Kojima H;
Acta Haematol; 2019; 141(2):111-118. PubMed ID: 30726834
[TBL] [Abstract][Full Text] [Related]
26. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
Shen M; Zhang J; Tang R; Wang Y; Zhan X; Fan S; Huang Z; Zhong Y; Li X
Cancer Med; 2022 Jun; 11(11):2173-2183. PubMed ID: 34655168
[TBL] [Abstract][Full Text] [Related]
27. Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Belch A; Bahlis N; White D; Cheung M; Chen C; Shustik C; Song K; Tosikyan A; Dispenzieri A; Anderson K; Brown D; Robinson S; Srinivasan S; Facon T
Cancer Med; 2020 Dec; 9(23):8923-8930. PubMed ID: 33049118
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Kumar SK; LaPlant BR; Reeder CB; Roy V; Halvorson AE; Buadi F; Gertz MA; Bergsagel PL; Dispenzieri A; Thompson MA; Crawley J; Kapoor P; Mikhael J; Stewart K; Hayman SR; Hwa YL; Gonsalves W; Witzig TE; Ailawadhi S; Dingli D; Go RS; Lin Y; Rivera CE; Rajkumar SV; Lacy MQ
Blood; 2016 Nov; 128(20):2415-2422. PubMed ID: 27702799
[TBL] [Abstract][Full Text] [Related]
29. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J;
Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675
[TBL] [Abstract][Full Text] [Related]
30. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.
Muchtar E; Gertz MA; LaPlant BR; Buadi FK; Leung N; O'Brien P; Bergsagel PL; Fonder A; Hwa YL; Hobbs M; Helgeson DK; Bradt EE; Gonsalves W; Lacy MQ; Kapoor P; Siddiqui M; Larsen JT; Warsame R; Hayman SR; Go RS; Dingli D; Kourelis TV; Dispenzieri A; Rajkumar SV; Kumar SK
Blood Adv; 2022 Sep; 6(18):5429-5435. PubMed ID: 35737873
[TBL] [Abstract][Full Text] [Related]
31. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
[TBL] [Abstract][Full Text] [Related]
32. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
[TBL] [Abstract][Full Text] [Related]
34. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Terpos E; Ramasamy K; Maouche N; Minarik J; Ntanasis-Stathopoulos I; Katodritou E; Jenner MW; Plonkova H; Gavriatopoulou M; Vallance GD; Pika T; Kotsopoulou M; Kothari J; Jelinek T; Kastritis E; Aitchison R; Dimopoulos MA; Zomas A; Hajek R
Ann Hematol; 2020 May; 99(5):1049-1061. PubMed ID: 32236735
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Muranushi H; Kanda J; Kobayashi M; Maeda T; Kitano T; Tsuji M; Ueda Y; Ishikawa T; Nohgawa M; Watanabe M; Imada K; Moriguchi T; Itoh M; Ohno H; Yonezawa A; Hirata H; Arima N; Asagoe K; Anzai N; Nagata K; Yasuno S; Kuwabara Y; Kitao H; Kim I; Kawagishi K; Ueshima K; Tominari S; Nakayama T; Yamashita K; Takaori-Kondo A
Hematology; 2022 Dec; 27(1):239-248. PubMed ID: 35152852
[TBL] [Abstract][Full Text] [Related]
36. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
[TBL] [Abstract][Full Text] [Related]
37. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.
Bringhen S; D'Agostino M; De Paoli L; Montefusco V; Liberati AM; Galieni P; Grammatico S; Muccio VE; Esma F; De Angelis C; Musto P; Ballanti S; Offidani M; Petrucci MT; Gaidano G; Corradini P; Palumbo A; Sonneveld P; Boccadoro M
Leukemia; 2018 Apr; 32(4):979-985. PubMed ID: 29263440
[TBL] [Abstract][Full Text] [Related]
38. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
[TBL] [Abstract][Full Text] [Related]
39. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.
Schjesvold F; Goldschmidt H; Maisnar V; Spicka I; Abildgaard N; Rowlings P; Cain L; Romanus D; Suryanarayan K; Rajkumar V; Odom D; Gnanasakthy A; Dimopoulos M
Eur J Haematol; 2020 May; 104(5):443-458. PubMed ID: 31880006
[TBL] [Abstract][Full Text] [Related]
40. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Alsina M; Landgren O; Raje N; Niesvizky R; Bensinger WI; Berdeja JG; Kovacsovics T; Vesole DH; Fang B; Kimball AS; Siegel DS
Am J Hematol; 2021 Feb; 96(2):226-233. PubMed ID: 33125764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
